Huons Co Ltd
Huons Co Ltd is a South Korean pharmaceutical company that develops, produces, and distributes prescription drugs, primarily in the domestic market.
Business. Huons Co Ltd (243070.KQ) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Huons Co Ltd (243070.KQ) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Huons maintains a conservative capital structure with a debt-to-equity ratio of 0.42, below the median for the pharmaceutical industry, and holds KRW 49.13 billion in cash and equivalents. However, the company's free cash flow is negative at KRW -12.47 billion, driven by capital expenditures of KRW -44.93 billion, which suggests ongoing investment in operations or expansion.
Profitability metrics show a return on equity (ROE) of 2.5% and a return on assets (ROA) of 1.5%, both below the industry median for pharmaceutical firms. The company's operating margin is 6.3% (KRW 9.31 billion operating income on KRW 148.98 billion revenue), which is in line with the sector average. Gross margin stands at 48.6% (KRW 72.35 billion gross profit on KRW 148.98 billion revenue), indicating strong cost control in production.
Geographically, Huons is heavily concentrated in the South Korean market, with no disclosed international revenue segments. The company's revenue is entirely derived from domestic operations, which exposes it to regulatory and economic risks specific to the Korean healthcare system.
Looking ahead, Huons is expected to maintain stable revenue growth, with analysts forecasting a mean EPS of KRW 3,393, slightly below the last actual EPS of KRW 3,600. The company's capital expenditure plans suggest continued investment in R&D and production infrastructure, which could support long-term growth but may pressure short-term liquidity.
The company faces moderate liquidity risk due to negative net cash (KRW -92.64 billion) after subtracting total debt. While dilution risk is currently low, the company's capital structure and free cash flow dynamics suggest a need for close monitoring of future financing activities.
Recent filings and transcripts indicate no major strategic shifts or regulatory challenges in the near term. The company's strong buy recommendation from one analyst and neutral stance from others suggest a cautiously optimistic outlook, though the absence of a consensus buy recommendation highlights uncertainty in the market.
- Huons maintains a conservative debt-to-equity ratio of 0.42, but negative free cash flow indicates ongoing capital investment.
- ROE of 2.5% and ROA of 1.5% are below the industry median, suggesting room for improvement in asset utilization and profitability.
- Revenue is entirely concentrated in South Korea, exposing the company to domestic regulatory and economic risks.
- Analysts remain cautiously optimistic, with one strong buy recommendation and no sell ratings, but no consensus on near-term growth.
- Liquidity risk is moderate due to negative net cash, and dilution risk is currently low.
Bull / Bear case
Generated · model-assistedRevenue grew 9.2% annually over four years, demonstrating consistent top-line expansion for the pharmaceutical company.
Net income surged 44.8% year-over-year in FY2026, indicating strong recent profitability improvement.
Cash conversion ratio of 1.96 ranks in the top quartile of the pharmaceutical cohort.
Free cash flow turned positive in FY2026, reaching 32.2 billion KRW after previous deficits.
Long-term debt increased significantly to 178.7 billion KRW in FY2025, raising leverage concerns.
The company faces high credit risk, signaling potential difficulties in meeting financial obligations.
Free cash flow was negative 41.7 billion KRW in FY2025, highlighting recent cash generation volatility.
In focus — financials by report
Revenue KRW 146.62B; Operating income KRW 11.01B.
- ▍Revenue KRW 146.62B
- ▍Operating income KRW 11.01B
- ▍Net margin 2.7%
Revenue KRW 146.87B; Operating income KRW 8.68B.
- ▍Revenue KRW 146.87B
- ▍Operating income KRW 8.68B
- ▍Net margin 4.9%
Revenue KRW 148.98B; Operating income KRW 9.31B.
- ▍Revenue KRW 148.98B
- ▍Operating income KRW 9.31B
- ▍Net margin 5.7%
Revenue KRW 620.77B, +5,2% YoY; Operating income +31,7% YoY.
- ▍Revenue KRW 620.77B, +5,2% YoY
- ▍Operating income +31,7% YoY
- ▍Net income +44,8% YoY
- ▍Free cash flow +177,1% YoY
- ▍Net margin 6.9%
Revenue KRW 590.23B, +6,9% YoY; Operating income −36,6% YoY.
- ▍Revenue KRW 590.23B, +6,9% YoY
- ▍Operating income −36,6% YoY
- ▍Net income −41,6% YoY
- ▍Free cash flow −416,1% YoY
- ▍Net margin 5.0%
Revenue KRW 552.01B, +12,1% YoY; Operating income +51,1% YoY.
- ▍Revenue KRW 552.01B, +12,1% YoY
- ▍Operating income +51,1% YoY
- ▍Net income +124,9% YoY
- ▍Free cash flow +234,5% YoY
- ▍Net margin 9.1%
Revenue KRW 492.39B, +12,7% YoY; Operating income −16,3% YoY.
- ▍Revenue KRW 492.39B, +12,7% YoY
- ▍Operating income −16,3% YoY
- ▍Net income −27,0% YoY
- ▍Free cash flow −173,9% YoY
- ▍Net margin 4.6%
Revenue KRW 436.91B; Operating income KRW 45.28B.
- ▍Revenue KRW 436.91B
- ▍Operating income KRW 45.28B
- ▍Net margin 7.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 3 393,00 |
| Revenue | —no estimate | —no estimate | 651,6B KRW |
| Operating income | —no estimate | —no estimate | 49,0B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Huons Co Ltd Market data — financials · 2026-05-26
- Huons Co Ltd Market data — analyst estimates · 2026-05-26